Amgen – This autumn 2021 EPS Estimates for Amgen Inc. Raised by Analyst (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) – SVB Leerink raised their This autumn 2021 earnings per share estimates for Amgen in a analysis word issued on Wednesday, December ninth. SVB Leerink analyst G. Porges now expects that the medical analysis firm will publish earnings per share of $4.12 for the quarter, up from their prior estimate of $4.09. SVB Leerink has a “Market Carry out” score and a $253.00 price goal on the stock. Amgen (NASDAQ:AMGN) final posted its quarterly earnings information on Monday, November 2nd. The medical analysis firm reported $4.37 EPS for the quarter, beating the consensus estimate of $3.75 by $0.62. Amgen had a web margin of 29.42% and a return on fairness of 95.55%. The enterprise had income of $6.42 billion for the quarter, in comparison with analysts’ expectations of $6.38 billion.
A number of different brokerages have additionally issued experiences on AMGN. BMO Capital Markets lowered their price goal on shares of Amgen from $308.00 to $304.00 and set an “outperform” score on the stock in a analysis word on Thursday, October 29th. Oppenheimer diminished their goal price on shares of Amgen from $280.00 to $274.00 and set an “outperform” score for the corporate in a analysis word on Monday, November 16th. Mizuho diminished their goal price on shares of Amgen from $260.00 to $215.00 and set a “impartial” score for the corporate in a analysis word on Monday, November 2nd. BidaskClub downgraded shares of Amgen from a “promote” score to a “sturdy promote” score in a analysis word on Saturday, October 17th. Lastly, JPMorgan Chase & Co. diminished their goal price on shares of Amgen from $232.00 to $222.00 and set a “impartial” score for the corporate in a analysis word on Thursday, October 29th. Three analysis analysts have rated the stock with a promote score, twelve have issued a maintain score and sixteen have given a purchase score to the stock. The stock presently has a median score of “Maintain” and a median price goal of $254.31.
Shares of AMGN stock opened at $228.16 on Friday. The corporate has a present ratio of two.28, a fast ratio of 1.88 and a debt-to-equity ratio of three.12. Amgen has a 1 yr low of $177.05 and a 1 yr excessive of $264.97. The agency’s fifty day transferring common price is $227.16 and its two-hundred day transferring common price is $238.12. The agency has a market capitalization of $132.83 billion, a P/E ratio of 18.40, a PEG ratio of 1.89 and a beta of 0.76.
Institutional traders have lately made adjustments to their positions within the stock. Advisory Alpha LLC purchased a brand new place in Amgen through the third quarter valued at about $25,000. JFG Wealth Administration LLC bought a brand new stake in Amgen within the third quarter worth roughly $28,000. Baron Monetary Group LLC bought a brand new stake in Amgen within the third quarter worth roughly $51,000. Paces Ferry Wealth Advisors LLC bought a brand new stake in Amgen within the third quarter worth roughly $52,000. Lastly, Demars Monetary Group LLC bought a brand new stake in Amgen within the 2nd quarter worth roughly $53,000. Institutional traders personal 71.72% of the corporate’s stock.
In different information, Director R Sanders Williams bought 250 shares of the corporate’s stock in a transaction dated Monday, November ninth. The shares have been bought at a median price of $242.40, for a complete value of $60,600.00. Following the sale, the director now straight owns 4,909 shares of the corporate’s stock, valued at roughly $1,189,941.60. The transaction was disclosed in a authorized submitting with the Securities & Trade Fee, which could be accessed by means of this hyperlink. 0.36% of the stock is owned by company insiders.
The agency additionally lately introduced a quarterly dividend, which was paid on Tuesday, December eighth. Stockholders of report on Monday, November 16th got a $1.60 dividend. This represents a $6.40 dividend on an annualized foundation and a dividend yield of two.81%. The ex-dividend date was Friday, November 13th. Amgen’s dividend payout ratio is presently 43.18%.
Amgen Firm Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on irritation, oncology/hematology, bone well being, heart problems, nephrology and neuroscience areas. The corporate’s merchandise embody Enbrel to deal with plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to deal with most cancers sufferers; Prolia to deal with postmenopausal girls with osteoporosis; Xgeva for skeletal-related occasions prevention; Aranesp to deal with a lower-than-normal variety of pink blood cells and anemia; KYPROLIS to deal with sufferers with relapsed or refractory a number of myeloma; Sensipar/Mimpara to deal with secondary hyperparathyroidism; and EPOGEN to deal with anemia brought on by persistent kidney illness.
Learn Extra: Buying and selling Stocks – What are share gainers?
This instantaneous information alert was generated by narrative science expertise and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to [email protected]